Chao Huang

Chao Huang is a seasoned professional in biopharmaceutical process development, currently serving as Senior Director at HilleVax since June 2024, where leadership in next-generation virus-like-particle vaccine development is a key focus. Prior experience includes Director at Ultragenyx Pharmaceutical Inc. from April 2020 to June 2024, overseeing rAAV-based gene therapy development and leading a twelve-person team. Chao Huang has also held various positions at Bristol-Myers Squibb from November 2010 to April 2020, advancing in roles from Scientist I to Senior Scientist, where significant contributions were made in monoclonal antibody and Fc fusion protein development. Earlier experience includes a research assistant role at the University of Rochester, culminating in a PhD in Biochemistry, along with multiple advanced degrees from the University of Rochester and Beijing Normal University.